

Zhanju Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/550045/publications.pdf>

Version: 2024-02-01

74
papers

4,479
citations

147566
31
h-index

110170
64
g-index

74
all docs

74
docs citations

74
times ranked

7412
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term exclusive enteral nutrition remodels the gut microbiota and alleviates TNBS-induced colitis in mice. <i>Food and Function</i> , 2022, 13, 1725-1740.	2.1	7
2	Natural Herbal Remedy Wumei Decoction Ameliorates Intestinal Mucosal Inflammation by Inhibiting Th1/Th17 Cell Differentiation and Maintaining Microbial Homeostasis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1061-1071.	0.9	12
3	The Development and Validation of Anti-paratuberculosis-nocardia Polypeptide Antibody [Anti-pTNP] for the Diagnosis of Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, , .	0.6	2
4	Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study. <i>BMC Gastroenterology</i> , 2022, 22, 44.	0.8	8
5	miR-31-5p axis as a novel biomarker for predicting the development and prognosis of sporadic early-onset colorectal cancer. <i>Oncology Letters</i> , 2022, 23, 157.	0.8	6
6	Differential Diagnosis of Crohn's Disease and Ulcerative Primary Intestinal Lymphoma: A Scoring Model Based on a Multicenter Study. <i>Frontiers in Oncology</i> , 2022, 12, 856345.	1.3	3
7	TRIM21 Is Decreased in Colitis-associated Cancer and Negatively Regulates Epithelial Carcinogenesis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 458-468.	0.9	30
8	Differences in inflammatory bowel diseases between East and West: a Chinese perspective. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2021, 29, 19-26.	0.8	0
9	Twist1 contributes to developing and sustaining corticosteroid resistance in ulcerative colitis. <i>Theranostics</i> , 2021, 11, 7797-7812.	4.6	13
10	Critical roles of bile acids in regulating intestinal mucosal immune responses. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110180.	1.4	38
11	Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn's disease. <i>Gut Microbes</i> , 2021, 13, 1-18.	4.3	47
12	Macrophage-derived EDA-A2 inhibits intestinal stem cells by targeting miR-494/EDA2R/β-catenin signaling in mice. <i>Communications Biology</i> , 2021, 4, 213.	2.0	9
13	Cyclosporine modulates neutrophil functions via the SIRT6-HIF1α glycolysis axis to alleviate severe ulcerative colitis. <i>Clinical and Translational Medicine</i> , 2021, 11, e334.	1.7	36
14	Editorial: Microbiome in IBD: From Composition to Therapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 721992.	1.6	0
15	Success of Cyclosporin and Tofacitinib Combination Therapy in a Patient With Severe Steroid-refractory Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e157-e158.	0.9	9
16	Perianal disease onset age is associated with distinct disease features and need for intestinal resection in perianal Crohn's disease: a ten-year hospital-based observational study in China. <i>BMC Gastroenterology</i> , 2021, 21, 376.	0.8	2
17	Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 390-399.	1.9	4
18	A Prognostic Model Based on Nine DNA Methylation-Driven Genes Predicts Overall Survival for Colorectal Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 779383.	1.1	6

#	ARTICLE	IF	CITATIONS
19	Survivin Impairs the Apoptotic Machinery in CD4 ⁺ T Cells of Patients with Ulcerative Colitis. <i>Journal of Innate Immunity</i> , 2020, 12, 226-234.	1.8	8
20	Crohn's disease exacerbated by IL-17 inhibitors in patients with psoriasis: a case report. <i>BMC Gastroenterology</i> , 2020, 20, 340.	0.8	7
21	Interplay of intestinal microbiota and mucosal immunity in inflammatory bowel disease: a relationship of frenemies. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093518.	1.4	16
22	Levels of TB-IGRA may help to differentiate between intestinal tuberculosis and Crohn's disease in patients with positive results. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092200.	1.4	10
23	Mucoadhesive-to-penetrating controllable peptosomes-in-microspheres co-loaded with anti-miR-31 oligonucleotide and Curcumin for targeted colorectal cancer therapy. <i>Theranostics</i> , 2020, 10, 3594-3611.	4.6	40
24	Secreted stromal protein ISLR promotes intestinal regeneration by suppressing epithelial Hippo signaling. <i>EMBO Journal</i> , 2020, 39, e103255.	3.5	34
25	Clinical Features of COVID-19-Related Liver Functional Abnormality. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1561-1566.	2.4	628
26	The Degree of Ulcerative Colitis Burden of Luminal Inflammation score is superior to predicting medium- to long-term prognosis in patients with active ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482098121.	1.4	8
27	Monocyte Chemoattractant Protein 1-Induced Protein 1 Is Highly Expressed in Inflammatory Bowel Disease and Negatively Regulates Neutrophil Activities. <i>Mediators of Inflammation</i> , 2020, 2020, 1-15.	1.4	11
28	Exosomes in Inflammatory Bowel Disease: What Have We Learned So Far?. <i>Current Drug Targets</i> , 2020, 21, 1448-1455.	1.0	6
29	Current diagnosis and management of Crohn's disease in China: results from a multicenter prospective disease registry. <i>BMC Gastroenterology</i> , 2019, 19, 145.	0.8	29
30	Small heat shock protein CRYAB inhibits intestinal mucosal inflammatory responses and protects barrier integrity through suppressing IKK β activity. <i>Mucosal Immunology</i> , 2019, 12, 1291-1303.	2.7	29
31	Microbiota Metabolite Short-Chain Fatty Acids Facilitate Mucosal Adjuvant Activity of Cholera Toxin through GPR43. <i>Journal of Immunology</i> , 2019, 203, 282-292.	0.4	46
32	Vasoactive intestinal peptide stabilizes intestinal immune homeostasis through maintaining interleukin-10 expression in regulatory B cells. <i>Theranostics</i> , 2019, 9, 2800-2811.	4.6	24
33	MicroRNA-125a suppresses intestinal mucosal inflammation through targeting ETS-1 in patients with inflammatory bowel diseases. <i>Journal of Autoimmunity</i> , 2019, 101, 109-120.	3.0	44
34	MicroRNA-31 Reduces Inflammatory Signaling and Promotes Regeneration in Colon Epithelium, and Delivery of Mimics in Microspheres Reduces Colitis in Mice. <i>Gastroenterology</i> , 2019, 156, 2281-2296.e6.	0.6	140
35	Interleukin-33 Promotes REG3 β Expression in Intestinal Epithelial Cells and Regulates Gut Microbiota. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 8, 21-36.	2.3	38
36	Risk factors for delayed hemorrhage after colonoscopic postpolypectomy: Polyp size and operative modality. <i>JGH Open</i> , 2019, 3, 61-64.	0.7	6

#	ARTICLE	IF	CITATIONS
37	Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells' Differentiation and Function in Induction of Colitis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1450-1461.	0.9	112
38	Whole Exome Sequencing of Ulcerative Colitis-associated Colorectal Cancer Based on Novel Somatic Mutations Identified in Chinese Patients. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1293-1301.	0.9	18
39	ATF4 Deficiency Promotes Intestinal Inflammation in Mice by Reducing Uptake of Glutamine and Expression of Antimicrobial Peptides. <i>Gastroenterology</i> , 2019, 156, 1098-1111.	0.6	67
40	Anti-TNF- α Monoclonal Antibody Therapy Improves Anemia through Downregulating Hepatocyte Hcpidin Expression in Inflammatory Bowel Disease. <i>Mediators of Inflammation</i> , 2019, 2019, 1-13.	1.4	17
41	Critical Role of CD6highCD4+ T Cells in Driving Th1/Th17 Cell Immune Responses and Mucosal Inflammation in IBD. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 510-524.	0.6	31
42	ROR γ t Represses IL-10 Production in Th17 Cells To Maintain Their Pathogenicity in Inducing Intestinal Inflammation. <i>Journal of Immunology</i> , 2019, 202, 79-92.	0.4	23
43	Critical role of ROCK2 activity in facilitating mucosal CD4 + T cell activation in inflammatory bowel disease. <i>Journal of Autoimmunity</i> , 2018, 89, 125-138.	3.0	33
44	CD177+ neutrophils suppress epithelial cell tumourigenesis in colitis-associated cancer and predict good prognosis in colorectal cancer. <i>Carcinogenesis</i> , 2018, 39, 272-282.	1.3	54
45	Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1733-1744.	0.9	39
46	CD177 ⁺ neutrophils as functionally activated neutrophils negatively regulate IBD. <i>Gut</i> , 2018, 67, 1052-1063.	6.1	159
47	MicroRNAs 15A and 16 ⁻¹ Activate Signaling Pathways That Mediate Chemotaxis of Immune Regulatory B cells to Colorectal Tumors. <i>Gastroenterology</i> , 2018, 154, 637-651.e7.	0.6	81
48	Tripartite motif-containing (TRIM) 21 negatively regulates intestinal mucosal inflammation through inhibiting TH1/TH17 cell differentiation in patients with inflammatory bowel diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1218-1228.e12.	1.5	46
49	Umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or -resistant ulcerative colitis patients. <i>Oncotarget</i> , 2018, 9, 15027-15035.	0.8	0
50	Clinical significance of soluble immunoglobulins A and G and their coated bacteria in feces of patients with inflammatory bowel disease. <i>Journal of Translational Medicine</i> , 2018, 16, 359.	1.8	42
51	Anti-TNF- α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease. <i>Mediators of Inflammation</i> , 2018, 2018, 1-12.	1.4	49
52	Neutrophils Promote Amphiregulin Production in Intestinal Epithelial Cells through TGF- β 2 and Contribute to Intestinal Homeostasis. <i>Journal of Immunology</i> , 2018, 201, 2492-2501.	0.4	34
53	Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis. <i>Nature Communications</i> , 2018, 9, 3555.	5.8	380
54	MicroRNA 301A Promotes Intestinal Inflammation and Colitis-Associated Cancer Development by Inhibiting BTG1. <i>Gastroenterology</i> , 2017, 152, 1434-1448.e15.	0.6	118

#	ARTICLE	IF	CITATIONS
55	Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. <i>Journal of Gastroenterology</i> , 2017, 52, 1-8.	2.3	632
56	CD99 refers to the activity of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 359-364.	0.6	19
57	Clinicopathological and Ileocolonoscopy Characteristics in Patients with Nodular Lymphoid Hyperplasia in the Terminal Ileum. <i>International Journal of Medical Sciences</i> , 2017, 14, 750-757.	1.1	7
58	Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease. <i>Mediators of Inflammation</i> , 2016, 2016, 1-14.	1.4	14
59	Commensal A4 bacteria inhibit intestinal Th2 cell responses through induction of dendritic cell TGF- β 2 production. <i>European Journal of Immunology</i> , 2016, 46, 1162-1167.	1.6	38
60	miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF- α in IBD. <i>Gut</i> , 2016, 65, 1938-1950.	6.1	137
61	Specific immunotherapy in combination with <i>Clostridium butyricum</i> inhibits allergic inflammation in the mouse intestine. <i>Scientific Reports</i> , 2015, 5, 17651.	1.6	42
62	Divalent metal-ion transporter 1 is decreased in intestinal epithelial cells and contributes to the anemia in inflammatory bowel disease. <i>Scientific Reports</i> , 2015, 5, 16344.	1.6	23
63	PPP1R12A Copy Number Is Associated with Clinical Outcomes of Stage III CRC Receiving Oxaliplatin-Based Chemotherapy. <i>Mediators of Inflammation</i> , 2015, 2015, 1-7.	1.4	8
64	Serum Levels of Lipopolysaccharide and 1,3- β -D-Glucan Refer to the Severity in Patients with Crohn's Disease. <i>Mediators of Inflammation</i> , 2015, 2015, 1-9.	1.4	46
65	Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn's Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa. <i>Mediators of Inflammation</i> , 2015, 2015, 1-9.	1.4	19
66	Insulin-like growth factor-1 endues monocytes with immune suppressive ability to inhibit inflammation in the intestine. <i>Scientific Reports</i> , 2015, 5, 7735.	1.6	45
67	Changes of immunocytic phenotypes and functions from human colorectal adenomatous stage to cancerous stage: Update. <i>Immunobiology</i> , 2015, 220, 1186-1196.	0.8	23
68	miR-10a inhibits dendritic cell activation and Th1/Th17 cell immune responses in IBD. <i>Gut</i> , 2015, 64, 1755-1764.	6.1	143
69	A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. <i>Gut</i> , 2014, 63, 1381-1392.	6.1	317
70	Prolactin mediates psychological stress-induced dysfunction of regulatory T cells to facilitate intestinal inflammation. <i>Gut</i> , 2014, 63, 1883-1892.	6.1	67
71	TLR4 regulates IFN- γ and IL-17 production by both thymic and induced Foxp3+ Tregs during intestinal inflammation. <i>Journal of Leukocyte Biology</i> , 2014, 96, 895-905.	1.5	41
72	Microbiota regulation of inflammatory bowel disease and colorectal cancer. <i>Seminars in Cancer Biology</i> , 2013, 23, 543-552.	4.3	45

#	ARTICLE	IF	CITATIONS
73	Interleukin (IL)-23 Suppresses IL-10 in Inflammatory Bowel Disease. <i>Journal of Biological Chemistry</i> , 2012, 287, 3591-3597.	1.6	41
74	The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity. <i>Journal of Leukocyte Biology</i> , 2011, 89, 597-606.	1.5	113